Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Fabricant heads NPA in interim

This article was originally published in The Tan Sheet

Executive Summary

Natural Products Association July 23 names VP of Scientific and Regulatory Affairs Daniel Fabricant as interim executive director and CEO as the trade group looks for a permanent replacement for David Seckman. "I'm tremendously excited, David has us in a great place, and I have been really fortunate to have had the opportunity to learn so much from him," Fabricant said in an e-mail. Fabricant, who has been with the association more than four years, moves to the position Aug. 3. Seckman leaves at the end of July, after nine years, to head the Food Processing Suppliers Association. NPA formed a search committee for a permanent executive director and CEO (1"The Tan Sheet" July 13, 2009)

You may also be interested in...



NPA's Seckman Recalls Decade Of Transition For Supplement Industry

David Seckman led the Natural Products Association during the dietary supplement industry's transition to working under good manufacturing practices and mandatory adverse event reporting and also during NPA's own transition to working in Washington

UK Set For January Brexit After Conservatives Win Election

The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.

Dainippon, SanBio Call Time On Stroke Cell Therapy Alliance

Japanese companies agree to discontinue regenerative cell therapy pact after high-profile Phase II failure, but SanBio will move ahead with development and Dainippon will hold onto ex-partner stake for now.

Topics

UsernamePublicRestriction

Register

PS103150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel